Mutations Predict Responses to mTOR Inhibitors in mRCC

May 29-June 2, 2015; Chicago, Illinois
Mutations in MTOR, TSC1, and TSC2, but not PTEN or PIK3CA, were associated with complete responses to mTOR inhibitors in patients with metastatic RCC.
Format: Microsoft PowerPoint (.ppt)
File Size: 467 KB
Released: June 4, 2015


Educational grant provided by:
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Novartis Pharmaceuticals Corporation

Related Content

Download slides from Clinical Care Options examining the optimal use of VEGFR-targeted TKIs in treating patients with solid organ tumors.

Tanios Bekaii-Saab Tanios Bekaii-Saab, MD, FACP Richard Finn, MD Elizabeth R. Plimack, MD, MS Released: November 15, 2019

In this activity from Clinical Care Options, experts discuss the latest data on treating solid organ tumors with VEGFR inhibitors.

Tanios Bekaii-Saab Tanios Bekaii-Saab, MD, FACP Richard Finn, MD Elizabeth R. Plimack, MD, MS Released: November 15, 2019

Download this free slideset by Elizabeth R. Plimack, MD, MS, for a summary of clinical data on the use of immune checkpoint inhibitor-based therapy for patients with metastatic urothelial carcinoma.

Elizabeth R. Plimack, MD, MS Released: November 7, 2019

Download this slideset by Matthew Galsky, MD, to see recent data and ongoing clinical trials with immune checkpoint inhibitors for patients with muscle-invasive bladder cancer.

Matthew Galsky, MD Released: November 7, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?